Elevatebio LLC and Affini-T Therapeutics Inc. have entered into a partnership to advance Affini-T's engineered T-cell therapies focused on KRAS, an oncogenic driver mutation in solid tumor cancers.
AZD-4820 was evaluated in a cell viability assay performed in 30 human cancer cell lines, defining 12 different types of cancer, and testing a dose-range of multiplicity of infection (MOI); potent oncolytic activity was observed with EC50 values of <0.1 MOI in nearly all of the tested cells.
Bonum Therapeutics Inc., a spinout of Good Therapeutics Inc., which Roche Holding AG acquired in August, has announced a US$93 million series A financing. Bonum is developing new therapies based on the proprietary platform of allosterically regulated, conditionally active therapeutics developed by Good Therapeutics. The core platform makes possible the engineering and development of a wide range of medicines.
At the recent Society for Immunotherapy of Cancer meeting, researchers from Dong-A ST Co. Ltd. presented preclinical data for the novel small-molecule general control nonderepressible 2 (GCN2) inhibitor, DA-4507, being developed for the treatment of cancer.
Elpiscience Biopharma Ltd.’s ES-005 is a new high-affinity monoclonal antibody (MAb) that blocks human lymphocyte-activated gene 3 (LAG3) from binding to several ligands, such as major histocompatibility complex class II (MHC-II), liver and lymph node sinusoidal endothelial cell C-type lectin (L SECtin) and fibrinogen like 1 (FGL1).
Biotheus Inc. has entered into a license and collaboration agreement with Hansoh Pharmaceuticals (Hansoh Pharmaceutical Group Co. Ltd.) for Biotheus' EGFR/MET bispecific antibody PM-1080 in Greater China, including mainland China, Hong Kong, Macao and Taiwan.
Researchers from Aligos Therapeutics Inc. have described the discovery of novel liver-targeted oral PD-L1 small-molecule inhibitors for the treatment of chronic hepatitis B and liver cancers.
RSS
